Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Market Cap	13.38B
Revenue (ttm)	2.87B
Net Income (ttm)	447.12M
Shares Out	229.57M
EPS (ttm)	1.37
PE Ratio	20.17
Forward PE	10.62
Dividend	0.86 (3.10%)
Ex-Dividend Date	Sep 20, 2024

Volume	268,000
Average Volume	950,180
Open	27.60
Previous Close	27.60
Day's Range	26.95 - 27.60
52-Week Range	23.55 - 42.95
Beta	0.77
RSI	52.67
Earnings Date	Mar 22, 2025

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,158
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2024, HKG:6826's revenue was 2.70 billion, an increase of 1.64% compared to the previous year's 2.65 billion. Earnings were 420.15 million, an increase of 0.97%.

Financial numbers in CNY